Sarepta Therapeutics is a U.S. commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates.
PORTLAND, Ore.--(BUSINESS WIRE)--March 8, 2007--AVI BioPharma Inc. (Nasdaq: AVII) today announced that the company will hold a conference call to discuss its 2006 fourth quarter and year end financial results on Thursday, March 15, 2007, at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time).
Cell-Culture Research Targets HIV-1 Vif and Tar Stem Loop PORTLAND, Ore.--(BUSINESS WIRE)--March 1, 2007--AVI BioPharma, Inc. (Nasdaq:AVII), presented research results titled "Morpholino Antisense Oligomers that Target the Lentiviral Vif Gene and Tar Stem Loop are Novel Antiretroviral Drug
PORTLAND, Ore. & OMAHA, Neb.--(BUSINESS WIRE)--Jan. 9, 2007--AVI BioPharma, Inc. (Nasdaq:AVII), and Eleos Inc. announced today a cross-license agreement for the development of antisense drugs targeting p53, a well-studied human protein that controls cellular response to genetic damage.
PORTLAND, Ore. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Dec. 20, 2006--AVI BioPharma, Inc. (Nasdaq:AVII), and Ercole Biotech, Inc., announced today a cross-license and collaboration agreement to identify and develop drugs that direct the splicing of messenger RNA (mRNA) to treat a variety
Publication of Preclinical Studies Demonstrate Efficacy in Disease Models PORTLAND, Ore.--(BUSINESS WIRE)--Dec. 7, 2006--AVI BioPharma, Inc. (Nasdaq: AVII) today announced the initiation of a clinical program for the treatment of Duchenne Muscular Dystrophy (DMD) using its ESPRIT (Exon Skipping
PORTLAND, Ore., Dec 04, 2006 (BUSINESS WIRE) -- AVI BioPharma, Inc. (Nasdaq: AVII), has executed a two-year $28 million research contract with the Defense Threat Reduction Agency (DTRA) of Fort Belvoir, Va., an agency of the United States Department of Defense (DoD).
Moderator: Denis Burger November 15, 2006 8:00 a.m. Pacific Time Operator: Ladies and gentlemen, welcome to the AVI BioPharma 2006 Third Quarter Financial Results conference call. At this time all participants are in a listen–only mode. Following management’s prepared remarks we will hold a Q&A
Antisense drugs targeting hepatitis C virus, West Nile virus, and the oncogene c-myc found in the CSF after systemic administration to humans PORTLAND, Ore.--(BUSINESS WIRE)--Nov. 10, 2006--AVI BioPharma, Inc. (Nasdaq:AVII), today announced human clinical trial results showing that three distinct
PORTLAND, Ore.--(BUSINESS WIRE)--Nov. 8, 2006--AVI BioPharma, Inc. (Nasdaq:AVII) today reported financial results for the three and nine months ended September 30, 2006. The net loss for the third quarter of 2006 was $6.8 million, or $0.13 per share, compared with a net loss for the third quarter
Presentations to Take Place at Rodman & Renshaw 8th Annual Global Healthcare Conference and Paulson Investment's 29th Annual Westergaard SmallCap Conference PORTLAND, Ore.--(BUSINESS WIRE)--Nov. 6, 2006--AVI BioPharma, Inc. (Nasdaq:AVII), President and COO Alan P.
This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent official corporate documents on file with the U.S. Securities and Exchange Commission.